A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults

Trial Profile

A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Jul 2018

At a glance

  • Drugs Dolutegravir (Primary) ; Emtricitabine/tenofovir; Lamivudine
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms Gemini 1
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 02 Jul 2018 According to Takeda Pharma Media release, based on the data from the CCT-101 Study and GEMINI 1 company has obtained a New Drug Application Approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for Entyvio (generic name: vedolizumab, development code: MLN0002) for the treatment of patients with moderately to severely active ulcerative colitis (UC) in Japan.
    • 14 Jun 2018 Primary endpoint has been met. (Percentage of subjects with plasma HIV 1 RNA 50 copies/milliliter at Week 48)
    • 08 Mar 2018 Planned End Date changed from 3 Feb 2024 to 3 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top